Stem cells, immortality, and the evolution of metastatic properties in breast cancer: telomere maintenance mechanisms and metastatic evolution

Abstract

Breast cancer is the most significant cause of cancer-related death in women around the world. The vast majority of breast cancer-associated mortality stems from metastasis, which remains an incurable disease state. Metastasis results from evolution of clones that possess the insidious properties required for dissemination and colonization of distant organs. These clonal populations are descended from breast cancer stem cells (CSCs), which are also responsible for their prolonged maintenance and continued evolution. Telomeres impose a lifespan on cells that can be extended when they are actively elongated, as occurs in CSCs. Thus, changes in telomere structure serve to promote the survival of CSCs and subsequent metastatic evolution. The selection of telomere maintenance mechanism (TMM) has important consequences not only for CSC survival and evolution, but also for their coordination of various signaling pathways that choreograph the metastatic cascade. Targeting the telomere maintenance machinery may therefore provide a boon to the treatment of metastatic breast cancer. Here we review the two major TMMs and the roles they play in the development of stem and metastatic breast cancer cells. We also highlight current and future approaches to targeting these mechanisms in clinical settings to alleviate metastatic breast cancers.

Keywords

Breast cancer / cancer evolution / cancer stem cells / metastasis / telomerase

References

[1] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries..CA Cancer J Clin2018;68:394-424

[2] Cianfrocca M.Prognostic and predictive factors in early-stage breast cancer..Oncologist2004;9:606-16

[3] Chaffer CL.A perspective on cancer cell metastasis..Science2011;331:1559-64

[4] Fidler IJ.The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited..Nat Rev Cancer2003;3:453-8

[5] Lambert AW,Weinberg RA.Emerging biological principles of metastasis..Cell2017;168:670-91 PMCID:PMC5308465

[6] Kim YN,Sung JY,Kim H.Anoikis resistance: an essential prerequisite for tumor metastasis..Int J Cell Biol2012;2012:306879 PMCID:PMC3296207

[7] Xie HY,Li DQ.Tumor microenvironment: driving forces and potential therapeutic targets for breast cancer metastasis..Chin J Cancer2017;36:36 PMCID:PMC5372254

[8] Gerlinger M,Dewhurst SM,Tomlinson I.Cancer: evolution within a lifetime..Annu Rev Genet2014;48:215-36

[9] Klein CA.Parallel progression of primary tumours and metastases..Nat Rev Cancer2009;9:302-12

[10] Turajlic S.Metastasis as an evolutionary process..Science2016;352:169-75

[11] Rosen JM.The increasing complexity of the cancer stem cell paradigm..Science2009;324:1670-3 PMCID:PMC2873047

[12] Bapat SA.Evolution of cancer stem cells..Semin Cancer Biol2007;17:204-13

[13] Pece S,Confalonieri S,Vecchi M.Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content..Cell2010;140:62-73

[14] Fillmore CM.Human breast cancer cell lines contain stem-like cells that self- renew, give rise to phenotypically diverse progeny and survive chemotherapy..Breast Cancer Res2008;10:R25 PMCID:PMC2397524

[15] Nowell PC.The clonal evolution of tumor cell populations..Science1976;194:23-8

[16] La Porta CAM.Complexity in cancer stem cells and tumor evolution: toward precision medicine..Semin Cancer Biol2017;44:3-9

[17] Poleszczuk J,Enderling H.Evolution and phenotypic selection of cancer stem cells..PLoS Comput Biol2015;11:e1004025 PMCID:PMC4351192

[18] Hwang-Verslues WW,Chang PH,Wang HH.Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers..PLoS One2009;4:e8377 PMCID:PMC2793431

[19] Gupta PB,Jiang G,Tao K.Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells..Cell2011;146:633-44

[20] Iliopoulos D,Wang G.Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion..Proc Natl Acad Sci U S A2011;108:1397-402 PMCID:PMC3029760

[21] Notta F,Wang JC,Doulatov S.Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells..Nature2011;469:362-7

[22] Anderson K,van Delft FW,Guo Y.Genetic variegation of clonal architecture and propagating cells in leukaemia..Nature2011;469:356-61

[23] Piccirillo SG,Cajola L,Redaelli S.Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution..Oncogene2009;28:1807-11

[24] Oskarsson T,Zhang XH,Tavazoie SF.Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs..Nat Med2011;17:867-74 PMCID:PMC4020577

[25] Malanchi I,Susanto E,Lehr HA.Interactions between cancer stem cells and their niche govern metastatic colonization..Nature2011;481:85-9

[26] Jang GB,Cho SD,Jung JY.Blockade of Wnt/beta-catenin signaling suppresses breast cancer metastasis by inhibiting CSC-like phenotype..Sci Rep2015;5:12465 PMCID:PMC5378883

[27] Xu L,Hu C,Fei X.WNT pathway inhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells..Int J Oncol2016;48:1175-86

[28] Zhao D,Sun J,Drews-Elger K.VEGF drives cancer-initiating stem cells through VEGFR-2/Stat3 signaling to upregulate Myc and Sox2..Oncogene2015;34:3107-19

[29] Elaimy AL,Chang C,Amante JJ.VEGF-neuropilin-2 signaling promotes stem-like traits in breast cancer cells by TAZ-mediated repression of the Rac GAP beta2- chimaerin..Sci Signal2018;11:eaao6897

[30] Wang Y,Li Y.Involvement of breast cancer stem cells in tumor angiogenesis..Oncol Lett2017;14:8150-5 PMCID:PMC5755209

[31] Liu M,Casimiro MC,Quong AA.The canonical NF-kappaB pathway governs mammary tumorigenesis in transgenic mice and tumor stem cell expansion..Cancer Res2010;70:10464-73 PMCID:PMC3010731

[32] Storci G,Mari S,Tavolari S.TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype..J Cell Physiol2010;225:682-91 PMCID:PMC2939957

[33] Rinkenbaugh AL.The NF-kappaB Pathway and Cancer Stem Cells..Cells2016;5:E16 PMCID:PMC4931665

[34] Zhou J,Gu P,Margolick JB.NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells..Breast Cancer Res Treat2008;111:419-27 PMCID:PMC3320112

[35] Parvani JG.Sox4, EMT programs, and the metastatic progression of breast cancers: mastering the masters of EMT..Breast Cancer Res2013;15:R72 PMCID:PMC3979076

[36] Taylor MA,Schiemann WP.The pathophysiology of epithelial-mesenchymal transition induced by transforming growth factor-beta in normal and malignant mammary epithelial cells..J Mammary Gland Biol Neoplasia2010;15:169-90 PMCID:PMC3721368

[37] Micalizzi DS.Epithelial-mesenchymal transition in development and cancer..Future oncology2009;5:1129-43

[38] Felipe Lima J,Bayani J.EMT in Breast Carcinoma-A Review..J Clin Med2016;5:E65 PMCID:PMC4961996

[39] Luo M,Li J,Huang S.VEGF/NRP-1axis promotes progression of breast cancer via enhancement of epithelial-mesenchymal transition and activation of NF-kappaB and beta-catenin..Cancer Lett2016;373:1-11

[40] Fantozzi A,Pisarsky L,Kunita A.VEGF-mediated angiogenesis links EMT-induced cancer stemness to tumor initiation..Cancer Res2014;74:1566-75

[41] Ponti D,Zaffaroni N,Petrangolini G.Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties..Cancer Res2005;65:5506-11

[42] Shay JW.Telomeres and telomerase in normal and cancer stem cells..FEBS Lett2010;584:3819-25 PMCID:PMC3370416

[43] Hannen R.Essential roles of telomerase reverse transcriptase hTERT in cancer stemness and metastasis..FEBS Lett2018;592:2023-31

[44] Bojovic B,Jin Y,Crowe DL.Alternative lengthening of telomeres in cancer stem cells in vivo..Oncogene2015;34:611-20 PMCID:PMC4135038

[45] de Lange T.How telomeres solve the end-protection problem..Science2009;326:948-52 PMCID:PMC2819049

[46] Griffith JD,Rosenfield S,Bianchi A.Mammalian telomeres end in a large duplex loop..Cell1999;97:503-14

[47] de Lange T.Shelterin: the protein complex that shapes and safeguards human telomeres..Genes Dev2005;19:2100-10

[48] O’Sullivan RJ.Telomeres: protecting chromosomes against genome instability..Nat Rev Mol Cell Biol2010;11:171-81 PMCID:PMC2842081

[49] Schmidt JC.Human telomerase: biogenesis, trafficking, recruitment, and activation..Genes Dev2015;29:1095-105 PMCID:PMC4470279

[50] Cho NW,Lampson MA.Interchromosomal homology searches drive directional ALT telomere movement and synapsis..Cell2014;159:108-21 PMCID:PMC4177039

[51] Dilley RL,Cho NW,Wondisford AR.Break-induced telomere synthesis underlies alternative telomere maintenance..Nature2016;539:54-8 PMCID:PMC5384111

[52] Cesare AJ,Cohen SB,Pickett HA.Spontaneous occurrence of telomeric DNA damage response in the absence of chromosome fusions..Nat Struct Mol Biol2009;16:1244-51

[53] Heaphy CM,Jiao Y,Edil BH.Altered telomeres in tumors with ATRX and DAXX mutations..Science2011;333:425 PMCID:PMC3174141

[54] Lovejoy CA,Reisenweber S,Bruno J.Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway..PLoS Genet2012;8:e1002772 PMCID:PMC3400581

[55] Subhawong AP,Argani P,Kouprina N.The alternative lengthening of telomeres phenotype in breast carcinoma is associated with HER-2 overexpression..Mod Pathol2009;22:1423-31

[56] Heaphy CM,Hong SM,Montgomery EA.Prevalence of the alternative lengthening of telomeres telomere maintenance mechanism in human cancer subtypes..Am J Pathol2011;179:1608-15 PMCID:PMC3181356

[57] Tanaka H,Huda N,Beam MJ.Telomere fusions in early human breast carcinoma..Proc Natl Acad Sci U S A2012;109:14098-103 PMCID:PMC3435165

[58] Gisselsson D,Petersen A,Dal Cin P.Telomere dysfunction triggers extensive DNA fragmentation and evolution of complex chromosome abnormalities in human malignant tumors..Proc Natl Acad Sci U S A2001;98:12683-8 PMCID:PMC60114

[59] Hampton OA,Miller CA,Li J.A sequence-level map of chromosomal breakpoints in the MCF-7 breast cancer cell line yields insights into the evolution of a cancer genome..Genome Res2009;19:167-77 PMCID:PMC2652200

[60] Cleal K,Baird D.Telomere length dynamics and the evolution of cancer genome architecture..Int J Mol Sci2018;19:E482 PMCID:PMC5855704

[61] Stephens PJ,Fu B,Bignell GR.Massive genomic rearrangement acquired in a single catastrophic event during cancer development..Cell2011;144:27-40 PMCID:PMC3065307

[62] Maciejowski J,Bosco N,de Lange T.Chromothripsis and kataegis induced by telomere crisis..Cell2015;163:1641-54 PMCID:PMC4687025

[63] Lafferty-Whyte K,Will MB,Daidone MG.A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT..Oncogene2009;28:3765-74 PMCID:PMC2875172

[64] Silvestre DC,Hoffschir F,Mouthon MA.Alternative lengthening of telomeres in human glioma stem cells..Stem Cells2011;29:440-51

[65] Robinson NJ.Means to the ends: The role of telomeres and telomere processing machinery in metastasis..Biochim Biophys Acta2016;1866:320-9 PMCID:PMC5138103

[66] Park JI,Hong JY,Jun S.Telomerase modulates Wnt signalling by association with target gene chromatin..Nature2009;460:66-72 PMCID:PMC4349391

[67] Ghosh A,Leow SC,Shin EM.Telomerase directly regulates NF- kappaB-dependent transcription..Nat Cell Biol2012;14:1270-81

[68] Ding D,Zhou J,Cong YS.Human telomerase reverse transcriptase regulates MMP expression independently of telomerase activity via NF-kappaB-dependent transcription..FASEB J2013;27:4375-83

[69] Hoffmeyer K,Rudloff S,Hierholzer A.Wnt/beta-catenin signaling regulates telomerase in stem cells and cancer cells..Science2012;336:1549-54

[70] Akiyama M,Hayashi T,Mitsiades CS.Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein..Cancer Res2003;63:18-21

[71] Liu N,Hao W,Wu X.hTERT promotes tumor angiogenesis by activating VEGF via interactions with the Sp1 transcription factor..Nucleic Acids Res2016;44:8693-703 PMCID:PMC5062966

[72] Wu KJ,Amacker M,Polack A.Direct activation of TERT transcription by c-MYC..Nat Genet1999;21:220-4

[73] Yin S,Xu L,Reddy KB.Myc mediates cancer stem-like cells and EMT changes in triple negative breast cancers cells..PLoS One2017;12:e0183578 PMCID:PMC5560738

[74] Yang A,Schulte BA,Tew KD.MYC Inhibition Depletes Cancer Stem- like Cells in Triple-Negative Breast Cancer..Cancer Res2017;77:6641-50 PMCID:PMC5712265

[75] Henson JD.Assaying and investigating alternative lengthening of telomeres activity in human cells and cancers..FEBS Lett2010;584:3800-11

[76] Xue Y,Zhang D,Chen Y.Twisted epithelial-to-mesenchymal transition promotes progression of surviving bladder cancer T24 cells with hTERT-dysfunction..PLoS One2011;6:e27748 PMCID:PMC3216997

[77] Lagunas AM,Crowe DL.Telomere DNA damage signaling regulates cancer stem cell evolution, epithelial mesenchymal transition, and metastasis..Oncotarget2017;8:80139-55 PMCID:PMC5655185

[78] El-Badawy A,Nasr MA,Ahmed TA.Telomerase reverse transcriptase coordinates with the epithelial-to-mesenchymal transition through a feedback loop to define properties of breast cancer stem cells..Biol Open2018;7:bio034181 PMCID:PMC6078341

[79] Nguyen GH,Robles AI,Gray LT.Regulation of gene expression by the BLM helicase correlates with the presence of G-quadruplex DNA motifs..Proc Natl Acad Sci U S A2014;111:9905-10 PMCID:PMC4103369

[80] Grudzien P,Albain KS,Rajan P.Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation..Anticancer Res2010;30:3853-67

[81] Jafri MA,Alqahtani MH.Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies..Genome Med2016;8:69 PMCID:PMC4915101

[82] Hochreiter AE,Goldblatt EM,Miller KD.Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer..Clin Cancer Res2006;12:3184-92

[83] Dogan F,Bagca BG,Sogutlu F.Investigation of the effect of telomerase inhibitor BIBR1532 on breast cancer and breast cancer stem cells..J Cell Biochem2018;

[84] Joseph I,Bassett E,Buseman CM.The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines..Cancer Res2010;70:9494-504

[85] Koziel JE.The telomerase inhibitor imetelstat alone, and in combination with trastuzumab, decreases the cancer stem cell population and self-renewal of HER2+ breast cancer cells..Breast Cancer Res Treat2015;149:607-18 PMCID:PMC4667948

[86] Cosme-Blanco W,Lazar AJ,Lozano G.Telomere dysfunction suppresses spontaneous tumorigenesis in vivo by initiating p53-dependent cellular senescence..EMBO Rep2007;8:497-503 PMCID:PMC1866197

[87] Schmidt-Kittler O,Daskalakis A,Ahr A.From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression..Proc Natl Acad Sci U S A2003;100:7737-42 PMCID:PMC164657

[88] Griffith JK,Fordyce CA,Joste NE.Reduced telomere DNA content is correlated with genomic instability and metastasis in invasive human breast carcinoma..Breast Cancer Res Treat1999;54:59-64

[89] Zeng X,Xu M,Baus D.Administration of a nucleoside analog promotes cancer cell death in a telomerase-dependent manner..Cell Rep2018;23:3031-41 PMCID:PMC6072277

[90] Ruden M.Novel anticancer therapeutics targeting telomerase..Cancer Treat Rev2013;39:444-56

[91] Vonderheide RH.Telomerase as a universal tumor-associated antigen for cancer immunotherapy..Oncogene2002;21:674-9

[92] Mender I,Dikmen ZG,Shay JW.Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2’-deoxyguanosine..Cancer Discov2015;5:82-95 PMCID:PMC4293221

[93] Zanetti M.A second chance for telomerase reverse transcriptase in anticancer immunotherapy..Nat Rev Clin Oncol2017;14:115-28

[94] Sandri S,Moxley K,De Sanctis F.Feasibility of telomerase-specific adoptive t-cell therapy for b-cell chronic lymphocytic leukemia and solid malignancies..Cancer Res2016;76:2540-51

[95] Flynn RL,Jeitany M,Bryll AR.Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors..Science2015;347:273-7 PMCID:PMC4358324

[96] Drosopoulos WC,Schildkraut CL.BLM helicase facilitates telomere replication during leading strand synthesis of telomeres..J Cell Biol2015;210:191-208 PMCID:PMC4508891

[97] Pan X,Sethi L,Schildkraut CL.FANCM, BRCA1, and BLM cooperatively resolve the replication stress at the ALT telomeres..Proc Natl Acad Sci U S A2017;114:E5940-E9 PMCID:PMC5530707

[98] Nguyen GH,Rosenthal AS,Singh DK.A small molecule inhibitor of the BLM helicase modulates chromosome stability in human cells..Chem Biol2013;20:55-62 PMCID:PMC3558928

[99] Temime-Smaali N,Wenner T,Douarre C.Topoisomerase IIIalpha is required for normal proliferation and telomere stability in alternative lengthening of telomeres..EMBO J2008;27:1513-24 PMCID:PMC2396391

[100] Tsai HJ,Li TK,Wu KJ.Involvement of topoisomerase III in telomere-telomere recombination..J Biol Chem2006;281:13717-23

[101] Ward RJ.Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment..Mol Pharmacol2005;68:779-86